Milestone – Talk Bio

FDA Rejects Milestone Pharmaceuticals’ Etripamil Nasal Spray for PSVT

2 months ago talkbio0Tagged Cardamyst, Complete, etripamil, Milestone, Paroxysmal supraventricular tachycardia, Rejection, Response process, United States Food and Drug Administration

Etripamil, Cardamyst, PSVT, FDA rejection, Complete Response Letter, manufacturing issues, Milestone Pharmaceuticals

Milestone’s Etripamil Nasal Spray Advances Towards Regulatory Filing in China for PSVT Treatment

9 months ago talkbio0Tagged Cardiovascular system, China, etripamil nasal spray, Milestone, Paroxysmal, Paroxysmal supraventricular tachycardia, Pharmaceuticals Ltd, Regulatory Filing, Tenascin, human

Etripamil nasal spray, Paroxysmal supraventricular tachycardia (PSVT), Milestone Pharmaceuticals, Ji Xing Pharmaceuticals Ltd, China regulatory filing, Cardiovascular therapies

Merck KGaA Bolsters Protein Degradation Pipeline with $756M C4 Therapeutics Partnership

1 year ago talkbio0Tagged C4 Therapeutics, Collaboration, Low-Double Digit Tiered Royalties, Merck KGaA, mid-single, Milestone, oncogenic proteins, Targeted Protein Degradation, TORPEDO® Platform, upfront payment

Merck KGaA, C4 Therapeutics, Targeted Protein Degradation, Collaboration, $756M Deal, Oncogenic Proteins, TORPEDO® Platform, Mid-Single to Low-Double Digit Tiered Royalties, Upfront Payment: $16 Million, Potential Milestone Payments: Up to $740 Million